Savara (SVRA) Common Equity (2010 - 2026)
Savara (SVRA) posted quarterly Common Equity of $176.0 million for Q1 2026, up 19.07% year-over-year from $147.8 million in Q1 2025, and up 202443.68% quarter-over-quarter from -$87000.0 in Q4 2025.
Savara (SVRA) Common Equity (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Common Equity for 17 consecutive years, with $176.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 19.07% year-over-year to $176.0 million; the TTM figure through Mar 2026 stood at $176.0 million (up 19.07% YoY), while the FY2025 annual figure was -$87000.0, up 88.4% from the prior year.
- Common Equity grew to $176.0 million in Q1 2026 per SVRA's latest filing, from -$87000.0 in the prior quarter.
- Across five years, Common Equity topped out at $199.3 million in Q3 2024 and bottomed at -$750000.0 in Q4 2024.
- Historically, Common Equity has averaged $107.5 million across 5 years, with a median of $120.5 million in 2025.
- Annual changes were most pronounced in 2022 — Common Equity surged 2155460.0% — and 2024, when it tumbled 100.53%.
- Savara's Common Equity stood at $107.8 million in 2022, then jumped by 30.24% to $140.4 million in 2023, then tumbled by 100.53% to -$750000.0 in 2024, then jumped by 88.4% to -$87000.0 in 2025, then surged by 202443.68% to $176.0 million in 2026.
- Business Quant data shows SVRA's Common Equity at $176.0 million in Q1 2026, -$87000.0 in Q4 2025, and -$155000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 143.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 143.66 Mn |
| Mar 31, 2026 | 176.04 Mn |
| Dec 31, 2025 | -87,000.00 |
| Sep 30, 2025 | -155,000.00 |
| Jun 30, 2025 | 120.48 Mn |
| Mar 31, 2025 | 147.85 Mn |
| Dec 31, 2024 | -750,000.00 |
| Sep 30, 2024 | 199.35 Mn |
| Jun 30, 2024 | 101.73 Mn |
| Mar 31, 2024 | 121.86 Mn |
| Dec 31, 2023 | 140.37 Mn |
| Sep 30, 2023 | 146.54 Mn |
| Jun 30, 2023 | 87.72 Mn |
| Mar 31, 2023 | 98.26 Mn |
| Dec 31, 2022 | 107.78 Mn |
| Sep 30, 2022 | 116.51 Mn |
| Jun 30, 2022 | 127.04 Mn |
| Mar 31, 2022 | 136.48 Mn |
| Dec 31, 2021 | 5,000.00 |
| Sep 30, 2021 | 155.23 Mn |